Dr. Feigal has proven herself to be an extremely valuable asset to our clients, providing leadership to multi-disciplinary project teams as well as critical guidance in the design of optimal development programs and regulatory pathways.
Rochelle, Virginia (PRWEB) July 20, 2015
Carl Peck, MD, Chairman of NDA Partners LLC, announced today that Ellen Feigal, MD has been appointed a Partner in the firm. Dr. Feigal is an internationally recognized expert in therapeutic product development, hematology-oncology, neurodegenerative and metabolic diseases, cell therapies, and regulatory science.
Before joining NDA Partners in January as a Premier Expert Consultant, she held a number of senior executive positions including Senior Vice President of Research and Development at the California Institute for Regenerative Medicine; Executive Medical Director, Global Development, at Amgen; and Chief Medical Officer at Insys Therapeutics. Dr. Feigal was a founding Director of the American Course on Drug Development and Regulatory Sciences.
She has worked in clinical research and product development as faculty at the University of California, San Francisco and San Diego and in positions at the Federal Government and non-profit institutes including Director of Medical Devices and Imaging at the Critical Path Institute, and Vice President of Clinical Sciences and Deputy Scientific Director at the Translational Genomics Research Institute. She directed the National Cancer Institute's (NCI) Division of Cancer Treatment and Diagnosis after serving as Deputy Director, and was a senior investigator in the Cancer Therapy Evaluation Program. She currently is an Adjunct Professor of Law at the Sandra Day O’Connor College of Law, at Arizona State University.
According to Dr. Peck, “Dr. Feigal has proven herself to be an extremely valuable asset to our clients with products in the early stages of development, providing leadership to multi-disciplinary project teams as well as critical guidance in the design of optimal development programs and regulatory pathways. We are pleased to welcome her as a new Partner and look forward to her continued leadership in this new role.”
In her expanded role at NDA Partners, Dr. Feigal will lead the firm’s efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology, and oncology.
About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of approximately 60 former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical development, toxicology, pharmacokinetics, CMC, clinical development, regulatory submissions, and development program management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.